These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7919225)

  • 21. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Product Approvability Recommendations From FDA Advisory Committees:: Inconsistently Sought, Indirectly Obtained.
    Gulfo JV; Briggeman J; Gamie A
    Ther Innov Regul Sci; 2018 Nov; 52(6):784-792. PubMed ID: 29714584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Withdrawing FDA approval of midodrine after marketing.
    Holtzman NA; Starfield B
    JAMA; 2011 Feb; 305(8):781-2; author reply 782. PubMed ID: 21343575
    [No Abstract]   [Full Text] [Related]  

  • 26. Cochlear implants: overview of safety and effectiveness. The FDA evaluation.
    Yin L; Segerson DA
    Otolaryngol Clin North Am; 1986 May; 19(2):423-33. PubMed ID: 3520445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop.
    Fed Regist; 1998 Aug; 63(154):42773-4. PubMed ID: 10182565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory considerations in vaccine design.
    Davenport LW
    Pharm Biotechnol; 1995; 6():81-96. PubMed ID: 7551250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and drug administration approval process for dermatology drugs in the United States.
    Boozalis E; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
    Kurzrock R; Pilat S; Bartolazzi M; Sanders D; Van Wart Hood J; Tucker SD; Webster K; Mallamaci MA; Strand S; Babcock E; Bast RC
    J Clin Oncol; 2009 Sep; 27(26):4433-40. PubMed ID: 19652061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis.
    Poole D; Bertolini G; Garattini S
    Lancet Infect Dis; 2009 Jan; 9(1):67-72. PubMed ID: 19095197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Missing data issues at the FDA Center for Biologics Evaluation and Research.
    Scott JA; Hsu H
    J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 38. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 39. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.